Skip to main content

7 Result(s)

within RLH Bolhuis Remove this filter

and

  1. No Access

    Article

    A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

    The clinical benefit of adoptive transfer of MHC-restricted cytotoxic T lymphocytes(CTL) for the treatment of cancer is hampered by the low success rate to generate antitumor CTLs. To bypass the need for tumor...

    RA Willemsen, R Debets, E Hart, HR Hoogenboom, RLH Bolhuis, P Chames in Gene Therapy (2001)

  2. No Access

    Article

    Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation

    CD134 (OX40) is a member of the tumor necrosis factor family which is expressed by activated T lymphocytes. CD134 expression on T cells was monitored during the first 35 days post-transplant in 14 patients, re...

    APA Gadisseur, JW Gratama, C Lamers, JWJ van Esser… in Bone Marrow Transplantation (1999)

  3. Article

    Genetic re-targeting of T lymphocyte specifity

    RLH Bolhuis, JW Gratama in Gene Therapy (1998)

    Download PDF (126 KB)

  4. No Access

    Article

    A retroviral vector system ‘STITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes

    Genetic engineering of T lymphocytes for adoptive clinical immunotherapy calls for efficient gene transduction methods. Therefore, a transient retroviral gene transduction system ‘STITCH’ was developed compris...

    MEM Weijtens, RA Willemsen, EH Hart, RLH Bolhuis in Gene Therapy (1998)

  5. No Access

    Article

    A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients

    We investigated the reconstitutive potential of haematopoietic progenitor cells collected in autologous whole blood during multicycle dose-intensified chemotherapy. Forty patients with metastatic solid tumours...

    R de Wit, WHJ Kruit, CHJ Lamers, MB van 't Veer, AA Luyten… in British Journal of Cancer (1998)

  6. No Access

    Article

    Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

    Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every ...

    WHJ Kruit, CJA Punt, SH Goey, PHM de Mulder, JW Gratama… in British Journal of Cancer (1996)

  7. No Access

    Article

    Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

    Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was administered ...

    SH Goey, AMM Eggermont, CJA Punt, R Slingerland, JW Gratama… in British Journal of Cancer (1995)